ArticleScientific reports2022
Effect of smoking on the development and outcomes of inflammatory bowel disease in Taiwan: a hospital-based cohort study.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risk factors of inflammatory bowel disease complicating anemia: A systematic review and meta-analysis.Medicine · 2026Pooled it
- Inflammatory bowel disease treatment: Mechanisms to clinical translation (Review).International journal of molecular medicine · 2026Review
- Combining Network Pharmacology, Molecular Docking, and Integrative Studies to Explore the Mechanism ofFood science & nutrition · 2025Article
- The gut immune axis in ulcerative colitis: insights from microbiome research.Molecular biology reports · 2025Review
- The Correlation between Hidradenitis Suppurativa and Irritable Bowel Diseases: A Systematic Review.The Journal of clinical and aesthetic dermatology · 2025Review
- Crohn's disease but not ulcerative colitis elevated risk of end-stage renal disease and mortality: A Taiwan retrospective cohort study.Medicine · 2025Observational
- MASLD risk prediction in IBD: development of two tailored clinical scores.Archive of clinical cases · 2025Article
- What Is the Real Impact of Smoking on Diseases Alleged to Benefit from It?European addiction research · 2025Review
- Switching from Cigarettes to Heated Tobacco Products in Japan-Potential Impact on Health Outcomes and Associated Health Care Costs.Healthcare (Basel, Switzerland) · 2024Article
- Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023.Intestinal research · 2024Article
- The Role of the Microbiome in the Pathogenesis and Treatment of Ulcerative Colitis-A Literature Review.Biomedicines · 2023Review
- Diet effects on colonic health influence the efficacy of Bin1 mAb immunotherapy for ulcerative colitis.Scientific reports · 2023Article
- Tobacco use in Crohn's disease patients and association with disease outcomes in the United States Medicaid population, 2010-2019.JGH open : an open access journal of gastroenterology and hepatology · 2023Article
- The national burden of inflammatory bowel disease in the United States from 1990-2019: results from the Global Burden of Disease study database.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Smoking influences the risks of inflammatory bowel disease (IBD). A hospital-based cohort was conducted to evaluate the effect of smoking on the development and outcomes of IBD, with age, sex and comorbidities matched non-IBD controls from the National Health Interview Survey database of Taiwan. 700 IBD patients (360 ulcerative colitis (UC), 340 Crohn's disease (CD)) were analyzed for outcomes; and 575 patients (297 UC, 278 CD) were analyzed for prevalence. Smoking prevalence was significantly lower in UC patients than controls (20.9% vs. 30.4%, p < 0.01), but no difference between CD patients and controls (19.8% vs. 22.1%, p = 0.60). UC smokers had fewer admissions (1.6 vs. 2.5, p < 0.05) but higher rates of new cancer development (16% vs. 6.7%, p < 0.05) and mortality (16% vs. 4.9%, p < 0.01) than nonsmokers. CD smokers tended to have higher rates of stricturing and penetrating diseases (p < 0.05), and higher surgery risk (60.3% vs. 38.3%, p < 0.01) than nonsmokers. Smoking prevents UC occurrence and is associated with fewer hospitalization but increases risks of cancer and mortality. By contrast, smoking does not affect CD occurrence but is related to more aggressive behavior which results in a higher surgical rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.